Rexahn Pharmaceuticals, Inc. (RNN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
35 Pages - GLDATA56213
$250.00

Summary

Rexahn Pharmaceuticals, Inc. (Rexahn Pharmaceuticals) is a biopharmaceutical company that develops therapeutics for the treatment of cancer. The company’s clinical development pipeline consists of three novel compounds such as Supinoxin, RX-3117 and Archexin. Its pipeline product portfolio indicates small molecule that blocks tumor progression and metastasis for melanoma; cancer cell specific nucleoside that inhibits DNA and RNA synthesis and induces apoptotic cell death; and an anti-cancer drug candidate that inhibits the activated form of the cancer cell signaling protein phosphorylated-Akt1. The company’s products are used for the treatment of ovary, kidney and pancreatic cancers. Rexahn Pharmaceuticals is headquartered in Rockville, Maryland, the US.

Rexahn Pharmaceuticals, Inc. (RNN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Rexahn Pharma Enters Into Licensing Agreement With Ohio State Innovation Foundation For Oligonucleotide Drug Delivery Platform 10
Rexahn Pharma Terminates Licensing Agreement With Teva Pharma For RX-3117 11
Rexahn Pharma Enters Into Licensing Agreement With University of Maryland For Nano-Polymer-Drug Conjugate Systems 13
Equity Offering 14
Rexahn Pharma Raises USD5 Million in Private Placement of Units 14
Rexahn Pharma to Raise up to USD7 Million in Private Placement of Units 16
Rexahn Pharma to Raise USD40 Million in Public Offering of Shares 18
Rexahn Pharma Completes Private Placement Of Units For US$20 Million 20
Rexahn Pharma Completes Private Placement Of Units For US$5.3 Million 22
Rexahn Pharma Completes Public Offering Of Units For US$5.7 Million 23
Rexahn Pharma Completes Public Offering Of Common Stock For US$6.6 Million 25
Rexahn Pharma Completes Registered Direct Offering Of Units For US$10 Million 27
Rexahn Pharma Completes Private Placement For US$10 Million 29
Acquisition 31
Pfizer Rumored To Acquire Rexahn Pharma 31
Rexahn Pharmaceuticals, Inc. - Key Competitors 32
Key Employees 33
Locations And Subsidiaries 34
Head Office 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts 1
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Rexahn Pharmaceuticals, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Rexahn Pharma Enters Into Licensing Agreement With Ohio State Innovation Foundation For Oligonucleotide Drug Delivery Platform 10
Rexahn Pharma Terminates Licensing Agreement With Teva Pharma For RX-3117 11
Rexahn Pharma Enters Into Licensing Agreement With University of Maryland For Nano-Polymer-Drug Conjugate Systems 13
Rexahn Pharma Raises USD5 Million in Private Placement of Units 14
Rexahn Pharma to Raise up to USD7 Million in Private Placement of Units 16
Rexahn Pharma to Raise USD40 Million in Public Offering of Shares 18
Rexahn Pharma Completes Private Placement Of Units For US$20 Million 20
Rexahn Pharma Completes Private Placement Of Units For US$5.3 Million 22
Rexahn Pharma Completes Public Offering Of Units For US$5.7 Million 23
Rexahn Pharma Completes Public Offering Of Common Stock For US$6.6 Million 25
Rexahn Pharma Completes Registered Direct Offering Of Units For US$10 Million 27
Rexahn Pharma Completes Private Placement For US$10 Million 29
Pfizer Rumored To Acquire Rexahn Pharma 31
Rexahn Pharmaceuticals, Inc., Key Competitors 32
Rexahn Pharmaceuticals, Inc., Key Employees 33

List of Figures
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Rexahn Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838